english.prescrire.org > Spotlight > Archives : 2017 > Advanced ovarian cancers: olaparib negatively impacts the quality of life, without prolonging survival

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2017 : 1 | 30 | 60

Advanced ovarian cancers: olaparib negatively impacts the quality of life, without prolonging survival

According to the current, very limited knowledge, the harm-benefit balance of olaparib is unfavourable for patients in remission from ovarian cancer treated with chemotherapy.

Only one patient in four is still alive five years after the diagnosis of advanced ovarian cancer, i.e. which has spread outside the pelvis, whether or not it has metastasised.

The reference treatment is surgical removal, when feasible. Post surgery, cytotoxic platinum-based chemotherapy prolongs life for a short time. But when the diagnosis is made at an advanced stage, around three women out of four experience a relapse following the initial chemotherapy. When this relapse occurs after 6 months (so-called platinum-sensitive cancer), another round of platinum-based chemotherapy, possibly combined with paclitaxel, is the first-choice treatment. After this chemotherapy, there is no evidence that continuous treatment is effective.

Ovarian cancer patients having had at least two courses of chemotherapy have huge expectations, because the disease is fatal in the short term and there is no truly satisfactory treatment. Even so, the evaluation of olaparib relies on a single randomised comparative trial, which did not show any prolongation of life, including in the presence of a deleterious mutation of a BRCA gene. An ex-post analysis, by nature inconclusive, suggested a longer gap between chemotherapy courses. Above all, olaparib exposes patients in remission to frequent adverse effects similar to those of chemotherapy, some of which are fatal.

In the absence of any proven efficacy, it is better to spare patients treatment with olaparib.

©Prescrire 1 January 2017

"Olaparib (Lynparza°). Ovarian cancer: spare patients who are in remission" Prescrire Int 2017; 26 (178): 9-12. (Pdf, subscribers only).
Download the full review.
Pdf, subscribers only

See also:

Bevacizumab and relapsed
ovarian cancer. Too many
serious and life-threatening
adverse effects
Prescrire Int 2013:
22 (144): 289
Pdf, subscribers only

Bevacizumab and advanced-
stage ovarian cancer.
Yet another oncological
indication, but still best
to avoid using this drug
Prescrire Int 2013:
22 (136): 64-67
Pdf, subscribers only

Measuring the quality of life
of cancer patients: interpret
the results with caution
Prescrire Int 2013:
19 (108): 188-190.
Pdf, subscribers only

Effects of cancer drugs
on survival: often
poorly evaluated
Prescrire Int 2009:
18 (102): 180-183.
Pdf, subscribers only